Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1999-03-04
1999-11-23
Gerstl, Robert
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
540599, 544 61, 544115, 544346, C07D47114, A61K 3150
Patent
active
059901098
ABSTRACT:
Novel heterocyclo-substituted imidazopyrazines and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic disorders.
REFERENCES:
patent: 4160097 (1979-07-01), Warner et al
patent: 4172947 (1979-10-01), Warner et al.
patent: 4191766 (1980-03-01), Warner et al.
patent: 4191767 (1980-03-01), Warner et al.
patent: 4197403 (1980-04-01), Warner et al.
patent: 4198508 (1980-04-01), Warner et al.
patent: 4200750 (1980-04-01), Warner et al.
patent: 4225724 (1980-09-01), Warner et al.
patent: 4229452 (1980-10-01), Warner et al.
patent: 4236015 (1980-11-01), Warner et al.
patent: 4317682 (1982-03-01), Katsura et al.
patent: 4440929 (1984-04-01), Lee et al.
patent: 5034530 (1991-07-01), Hansen et al.
patent: 5276028 (1994-01-01), Hansen
Bolen,J. B., et al., FASEB Journal, "The Src family of tyrosine protein kinases in hemopoietic signal transduction", vol. 6, pp. 3403-3409 (1992).
Chan, A.C., et al., EMBO Journal, "Activation of ZAP-70 kinase activity by phosphorylation of tyrosine 493 is required for lymphocyte antigen receptor function", vol. 14, pp. 2499-2508, (1995).
Ihle, J. N., Seminars in Immunology, "The Janus protein tyrosine kinases in hematopoietic cytokine", vol.7, pp. 247-254 (1995).
Iwashima, M., et al., Science, "Sequential Interactions of the TCR with Two Distinct Cytoplasmic Tyrosine Kinases", vol. 263, pp. 1136-1139 (1994).
Schieven, G. L., et al., Journal of Biological Chemistry, "ZAP-70 Tyrosine Kinase, CD45, and T Cell Receptor Involvement in UV-and H.sub.2 O.sub.2 -induced T Cell Signal Transduction", vol. 269, No. 32, pp. 20718-20726 (1994).
Ulrich, A., et al., Cell, "Signal Transduction by Receptors with Tyrosine Kinase Activity", vol. 61, pp. 203-212 (1990).
Weiss, A., et al., Cell, "Signal Transduction by Lymphocyte Antigen Receptors", vol. 76, pp. 263-274 (1994).
Cooper, J. A., et al., Journal of Biological Chemistry, "Phosphorylation Sites in Enolase and Lactate Dehydrogenase Utilized by Tyrosine Protein Kinases in Vivo and In Vitro", vol. 259, No. 12, pp. 7835-7841 (1984).
Davey, D.D., et al. J.Med. Chem. "Novel Compounds Possessing Potent cAMP and cGMP Phosphodiesterase Inhibitory Activity. Synthesis and Cardiovascular Effects of a Series of Imidazo[1,2-a]quinnoxalinones and Imidazo[1,5-a]quinoxalinones and Their AZA Analogues" vol. 34, pp. 2671-2677 (1991).
U.S. Application Serial No. 09/097,338; "Imidazoquinoxaline Protein Tyrosine Kinase Inhibitors;" Filed Jun. 15, 1998.
U.S. Application Serial No. 09/094,797; "Imidazoquinoxaline Protein Tyrosine Kinase Inhibitors;" Filed Jun. 15, 1998.
Barrish Joel C.
Chen Ping
Iwanowicz Edwin J.
Norris Derek J.
Bristol-Myers Squibb Co.
Gerstl Robert
Sher Audrey F.
LandOfFree
Heterocyclo-substituted imidazopyrazine protein tyrosine kinase does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclo-substituted imidazopyrazine protein tyrosine kinase , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclo-substituted imidazopyrazine protein tyrosine kinase will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1222127